Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.
Yarchoan
R
R
Clinical Oncology Program, National Cancer Institute, Bethesda, MD.
Pluda
J M
JM
Perno
C F
CF
Mitsuya
H
H
Broder
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016049:Didanosine / Q000627:therapeutic use; D004351:Drug Resistance; D006678:HIV / Q000187:drug effects / Q000502:physiology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology; D012190:Retroviridae / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors; D006377:T-Lymphocytes, Helper-Inducer / Q000473:pathology; D014779:Virus Replication / Q000187:drug effects; D016047:Zalcitabine / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine